Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Sagent Pharmaceuticals' Orphenadrine Citrate Injection, USP.
Subscribe to our email newsletter
Orphenadrine is indicated as an adjunct to rest, physical therapy and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.
The company expects to roll out this product in the third quarter of 2011.
Sagent founder and chairman and CEO Yordon said this is another example of their commitment to the market by introducing a portfolio of quality injectable products.